Attention-deficit/hyperactivity disorder genomics: Update for clinicians

Current Psychiatry Reports

Volumn 14, Issue 5, 2012, Pages 579-589

  Elia, Josephine ^a   Sackett, Jillan ^b   Turner, Terri ^b   Schardt, Martin ^c   Tang, Shih Ching ^a   Kurtz, Nicole ^b   Dunfey, Maura ^b   McFarlane, Nadia A ^b   Susi, Aita ^b   Danish, David ^b   Li, Alice ^b   Nissley Tsiopinis, Jenelle ^b   Borgmann Winter, Karin ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^c TRINITY COLLEGE   (United States)

Author keywords

ADHD; ADHD comorbidity; Attention deficit hyperactivity disorder; Copy number variation; Epigenetics; Ethics laws; Genetics; Pharmacogenetics; Structural variants

Indexed keywords

AMPHETAMINE; ATOMOXETINE; CYCLIN DEPENDENT KINASE INHIBITOR 1C; DEXAMPHETAMINE; DOPAMINE 4 RECEPTOR; DOPAMINE 5 RECEPTOR; DOPAMINE TRANSPORTER; GLUCOCORTICOID; LEAD; METHYLPHENIDATE; MITOGEN ACTIVATED PROTEIN KINASE; PER2 PROTEIN; POLYCHLORINATED BIPHENYL; POTASSIUM CHANNEL HERG; PROTEIN BMAL1; SEROTONIN TRANSPORTER; SYNAPTOSOMAL ASSOCIATED PROTEIN 25;

ARTICLE; ATTENTION DEFICIT DISORDER; COMORBIDITY; COPY NUMBER VARIATION; DNA METHYLATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG METABOLISM; EPIGENETICS; GENE OVEREXPRESSION; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; GENOMICS; HERITABILITY; HETEROZYGOTE; HUMAN; HYPERACTIVITY; HYPERTENSION; LAW; MEDICAL ETHICS; NEUROTRANSMISSION; NONHUMAN; PHARMACOGENOMICS; PRENATAL EXPOSURE; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; TACHYCARDIA; UNSPECIFIED SIDE EFFECT; WEIGHT REDUCTION;

ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; EPIGENOMICS; ETHICS, MEDICAL; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; GENOMICS; GENOTYPE; HUMANS; SYNAPTIC TRANSMISSION;

EID: 84870783570     PISSN: 15233812     EISSN: 15351645     Source Type: Journal    
DOI: 10.1007/s11920-012-0309-4     Document Type: Article

References (132)

1. Biederman J, Faraone SV, Keenan K, Benjamin J, Krifcher B, Moore C, et al. Further evidence for family-genetic risk factors in attention deficit hyperactivity disorder. Patterns of comorbidity in probands and relatives psychiatrically and pediatrically referred samples. Arch Gen Psychiatry. 1992;49(9):728-38.
2. Lombroso PJ, Pauls DL, Leckman JF. Genetic mechanisms in childhood psychiatric disorders. J Am Acad Child Adolesc Psychiatry. 1994;33(7):921-38. (Pubitemid 24273898)
3. Faraone SV, Biederman J, Keenan K, Tsuang MT. A familygenetic study of girls with DSM-III attention deficit disorder. Am J Psychiatry. 1991;148(1):112-7.
4. Faraone SV, Biederman J, Chen WJ, Milberger S, Warburton R, Tsuang MT. Genetic heterogeneity in attention-deficit hyperactivity disorder (ADHD): gender, psychiatric comorbidity, and maternal ADHD. J Abnorm Psychol. 1995;104(2):334-45.
5. Faraone SV, Biederman J, Milberger S. An exploratory study of ADHD among second-degree relatives of ADHD children. Biol Psychiatry. 1994;35(6):398-402. (Pubitemid 24118468)
6. Sprich S, Biederman J, Crawford MH, Mundy E, Faraone SV. Adoptive and biological families of children and adolescents with ADHD. J Am Acad Child Adolesc Psychiatry. 2000;39 (11):1432-7.
7. Burt SA. Rethinking environmental contributions to child and adolescent psychopathology: a meta-analysis of shared environmental influences. Psychol Bull. 2009;135(4):608-37. Epub 2009/07/10.
8. Faraone SV, Perlis RH, Doyle AE, Smoller JW, Goralnick JJ, Holmgren MA, et al. Molecular genetics of attention-deficit/hyperactivity disorder. Biol Psychiatry. 2005;57(11):1313-23. (Pubitemid 40798551)
9. Wood AC, Buitelaar J, Rijsdijk F, Asherson P, Kuntsi J. Rethinking shared environment as a source of variance underlying attentiondeficit/hyperactivity disorder symptoms: comment on Burt (2009). Psychol Bull. 2010;136(3):331-40. Epub 2010/05/05.
10. Anckarsater H, Lundstrom S, Kollberg L, Kerekes N, Palm C, Carlstrom E, et al. The Child and Adolescent Twin Study in Sweden (CATSS). Twin research and human genetics: the official journal of the International Society for Twin Studies. 2011;14(6):495-508. Epub 2012/04/18.
11. Larsson H, Anckarsater H, Rastam M, Chang Z, Lichtenstein P. Childhood attention-deficit hyperactivity disorder as an extreme of a continuous trait: a quantitative genetic study of 8,500 twin pairs. J Child Psychol Psychiatry. 2012;53(1):73-80. Epub 2011/09/20.
12. Nikolas MA, Burt SA. Genetic and environmental influences on ADHD symptom dimensions of inattention and hyperactivity: a meta-analysis. J Abnorm Psychol. 2010;119(1):1-17. Epub 2010/02/10.
13. Boomsma DI, Saviouk V, Hottenga JJ, Distel MA, de Moor MH, Vink JM, et al. Genetic epidemiology of attention deficit hyperactivity disorder (ADHD index) in adults. PLoS One. 2010;5(5):e10621. Epub 2010/05/21.
14. Young SE, Friedman NP, Miyake A, Willcutt EG, Corley RP, Haberstick BC, et al. Behavioral disinhibition: liability for externalizing spectrum disorders and its genetic and environmental relation to response inhibition across adolescence. J Abnorm Psychol. 2009;118(1):117-30. Epub 2009/02/19.
15. Derks EM, Hudziak JJ, Dolan CV, van Beijsterveldt TC, Verhulst FC, Boomsma DI. Genetic and environmental influences on the relation between attention problems and attention deficit hyperactivity disorder. Behav Genet. 2008;38(1):11-23. Epub 2007/12/13.
16. Ouellet-Morin I, Wigg KG, Feng Y, Dionne G, Robaey P, Brendgen M, et al. Association of the dopamine transporter gene and ADHD symptoms in a Canadian population-based sample of same-age twins. American journal of medical genetics Part B, Neuropsychiatric genetics: the official publication of the International Society of Psychiatric Genetics. 2008;147B(8):1442-9. Epub 2008/01/01.
17. Haberstick BC, Timberlake D, Hopfer CJ, Lessem JM, Ehringer MA, Hewitt JK. Genetic and environmental contributions to retrospectively reported DSM-IV childhood attention deficit hyperactivity disorder. Psychol Med. 2008;38(7):1057-66. Epub 2007/09/26. (Pubitemid 351769216)
18. Schultz MR, Rabi K, Faraone SV, Kremen W, Lyons MJ. Efficacy of retrospective recall of attention-deficit hyperactivity disorder symptoms: a twin study. Twin research and human genetics: the official journal of the International Society for Twin Studies. 2006;9(2):220-32. Epub 2006/04/14.
19. Ehringer MA, Rhee SH, Young S, Corley R, Hewitt JK. Genetic and environmental contributions to common psychopathologies of childhood and adolescence: a study of twins and their siblings. J Abnorm Child Psychol. 2006;34(1):1-17. Epub 2006/02/09. (Pubitemid 43800460)
20. Knopik VS, Sparrow EP, Madden PA, Bucholz KK, Hudziak JJ, Reich W, et al. Contributions of parental alcoholism, prenatal substance exposure, and genetic transmission to child ADHD risk: a female twin study. Psychol Med. 2005;35(5):625-35. Epub 2005/05/28. (Pubitemid 40716426)
21. Kuntsi J, Rijsdijk F, Ronald A, Asherson P, Plomin R. Genetic influences on the stability of attention-deficit/hyperactivity disorder symptoms from early to middle childhood. Biol Psychiatry. 2005;57(6):647-54. Epub 2005/03/23. (Pubitemid 40409703)
22. Dick DM, Viken RJ, Kaprio J, Pulkkinen L, Rose RJ. Understanding the covariation among childhood externalizing symptoms: genetic and environmental influences on conduct disorder, attention deficit hyperactivity disorder, and oppositional defiant disorder symptoms. J Abnorm Child Psychol. 2005;33(2):219-29. Epub 2005/04/21. (Pubitemid 40558436)
23. Price TS, Simonoff E, Asherson P, Curran S, Kuntsi J, Waldman I, et al. Continuity and change in preschool ADHD symptoms: longitudinal genetic analysis with contrast effects. Behav Genet. 2005;35(2):121-32. Epub 2005/02/03. (Pubitemid 40645674)
24. Saudino KJ, Ronald A, Plomin R. The etiology of behavior problems in 7-year-old twins: substantial genetic influence and negligible shared environmental influence for parent ratings and ratings by same and different teachers. J Abnorm Child Psychol. 2005;33(1):113-30. Epub 2005/03/12. (Pubitemid 40558447)
25. Larsson JO, Larsson H, Lichtenstein P. Genetic and environmental contributions to stability and change of ADHD symptoms between 8 and 13 years of age: a longitudinal twin study. J Am Acad Child Adolesc Psychiatry. 2004;43(10):1267-75. Epub 2004/09/24. (Pubitemid 39281667)
26. Rietveld MJ, Hudziak JJ, Bartels M, van Beijsterveldt CE, Boomsma DI. Heritability of attention problems in children: longitudinal results from a study of twins, age 3 to 12. J Child Psychol Psychiatry. 2004;45(3):577-88. Epub 2004/04/02. (Pubitemid 38380134)
27. Greven CU, Asherson P, Rijsdijk FV, Plomin R. A longitudinal twin study on the association between inattentive and hyperactive-impulsive ADHD symptoms. J Abnorm Child Psychol. 2011;39(5):623-32. Epub 2011/04/16.
28. van der Valk JC, Verhulst FC, Neale MC, Boomsma DI. Longitudinal genetic analysis of problem behaviors in biologically related and unrelated adoptees. Behav Genet. 1998;28(5):365-80. Epub 1999/02/02. (Pubitemid 29054781)
29. Hay DA, Bennett KS, Levy F, Sergeant J, Swanson J. A twin study of attention-deficit/hyperactivity disorder dimensions rated by the strengths and weaknesses of ADHD-symptoms and normal-behavior (SWAN) scale. Biol Psychiatry. 2007;61 (5):700-5. Epub 2006/09/12. (Pubitemid 46328855)
30. Gizer IR, Ficks C, Waldman ID. Candidate gene studies of ADHD: a meta-analytic review. Hum Genet. 2009;126(1):51-90. Epub 2009/06/10.
31. Eisenberg DT, Campbell B, Gray PB, Sorenson MD. Dopamine receptor genetic polymorphisms and body composition in undernourished pastoralists: an exploration of nutrition indices among nomadic and recently settled Ariaal men of northern Kenya. BMC Evol Biol. 2008;8:173. Epub 2008/06/12.
32. Altink ME, Rommelse NN, Slaats-Willemse DI, Vasquez AA, Franke B, Buschgens CJ, et al. The dopamine receptor D4 7-repeat allele influences neurocognitive functioning, but this effect is moderated by age and ADHD status: an exploratory study. The world journal of biological psychiatry: the official journal of the World Federation of Societies of Biological Psychiatry. 2012;13 (4):293-305. Epub 2011/11/25.
33. Krain AL, Castellanos FX. Brain development and ADHD. Clin Psychol Rev. 2006;26(4):433-44. Epub 2006/02/17.
34. Polderman TJ, Posthuma D, De Sonneville LM, Stins JF, Verhulst FC, Boomsma DI. Genetic analyses of the stability of executive functioning during childhood. Biol Psychol. 2007;76(1-2):11-20. Epub 2007/06/29. (Pubitemid 47268624)
35. Meador-Woodruff JH, Damask SP, Wang J, Haroutunian V, Davis KL, Watson SJ. Dopamine receptor mRNA expression in human striatum and neocortex. Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology. 1996;15(1):17-29. Epub 1996/07/01. (Pubitemid 26233387)
36. Thompson JL, Pogue-Geile MF, Grace AA. Developmental pathology, dopamine, and stress: a model for the age of onset of schizophrenia symptoms. Schizophr Bull. 2004;30(4):875-900. Epub 2005/06/15. (Pubitemid 40469523)
37. Asghari V, Sanyal S, Buchwaldt S, Paterson A, Jovanovic V, Van Tol HH. Modulation of intracellular cyclic AMP levels by different human dopamine D4 receptor variants. J Neurochem. 1995;65 (3):1157-65. Epub 1995/09/01.
38. Franke B, Neale BM, Faraone SV. Genome-wide association studies in ADHD. Hum Genet. 2009;126(1):13-50. Epub 2009/04/23.
39. Neale BM, Medland SE, Ripke S, Asherson P, Franke B, Lesch KP, et al. Meta-analysis of genome-wide association studies of attention-deficit/ hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2010;49(9):884-97. Epub 2010/08/25.
40. Hinney A, Scherag A, Jarick I, Albayrak O, Putter C, Pechlivanis S, et al. Genome-wide association study in German patients with attention deficit/hyperactivity disorder. Am J Med Genet B Neuropsychiatr Genet. 2011;156B(8):888-97. Epub 2011/10/21.
41. Stergiakouli E, Hamshere M, Holmans P, Langley K, Zaharieva I, Hawi Z, et al. Investigating the contribution of common genetic variants to the risk and pathogenesis of ADHD. Am J Psychiatry. 2012;169(2):186-94. Epub 2012/03/16.
42. Sharp AJ, Hansen S, Selzer RR, Cheng Z, Regan R, Hurst JA, et al. Discovery of previously unidentified genomic disorders from the duplication architecture of the human genome. Nat Genet. 2006;38(9):1038-42. (Pubitemid 44325929)
43. Eichler EE. Widening the spectrum of human genetic variation. Nat Genet. 2006;38(1):9-11. (Pubitemid 43011873)
44. Iafrate AJ, Feuk L, Rivera MN, Listewnik ML, Donahoe PK, Qi Y, et al. Detection of large-scale variation in the human genome. Nat Genet. 2004;36(9):949-51. (Pubitemid 39167488)
45. Sebat J, Lakshmi B, Troge J, Alexander J, Young J, Lundin P, et al. Large-scale copy number polymorphism in the human genome. Science. 2004;305(5683):525-8. (Pubitemid 38971344)
46. Perry GH, Dominy NJ, Claw KG, Lee AS, Fiegler H, Redon R, et al. Diet and the evolution of human amylase gene copy number variation. Nat Genet. 2007;39(10):1256-60. Epub 2007/09/11. (Pubitemid 47482688)
47. Stankiewicz P, Lupski JR. Structural variation in the human genome and its role in disease. Annu Rev Med. 2010;61:437-55. Epub 2010/01/12.
48. Williams NM, Zaharieva I, Martin A, Langley K, Mantripragada K, Fossdal R, et al. Rare chromosomal deletions and duplications in attention-deficit hyperactivity disorder: a genome-wide analysis. Lancet. 2010;376(9750):1401-8. Epub 2010/10/05.
49. Lesch KP, Selch S, Renner TJ, Jacob C, Nguyen TT, Hahn T, et al. Genome-wide copy number variation analysis in attentiondeficit/hyperactivity disorder: association with neuropeptide Y gene dosage in an extended pedigree. Mol Psychiatry. 2011;16 (5):491-503. Epub 2010/03/24.
50. Lionel AC, Crosbie J, Barbosa N, Goodale T, Thiruvahindrapuram B, Rickaby J, et al. Rare copy number variation discovery and cross-disorder comparisons identify risk genes for ADHD. Sci Transl Med. 2011;3(95):95ra75. Epub 2011/08/13.
51. Elia J, Glessner JT, Wang K, Takahashi N, Shtir CJ, Hadley D, et al. Genome-wide copy number variation study associates metabotropic glutamate receptor gene networks with attention deficit hyperactivity disorder. Nat Genet. 2012;44(1):78-84. Epub 2011/12/06.
52. Williams NM, Franke B, Mick E, Anney RJ, Freitag CM, Gill M, et al. Genome-wide analysis of copy number variants in attention deficit hyperactivity disorder: the role of rare variants and duplications at 15q13.3. Am J Psychiatry. 2012;169(2):195-204. Epub 2012/03/16.
53. Elia J, Gai X, Xie HM, Perin JC, Geiger E, Glessner JT, et al. Rare structural variants found in attention-deficit hyperactivity disorder are preferentially associated with neurodevelopmental genes. Mol Psychiatry. 2010;15(6):637-46. Epub 2009/06/24.
54. Feinberg AP, Tycko B. The history of cancer epigenetics. Nat Rev Cancer. 2004;4(2):143-53. Epub 2004/01/21. (Pubitemid 38198742)
55. Kelleher 3rd RJ, Bear MF. The autistic neuron: troubled translation? Cell. 2008;135(3):401-6. Epub 2008/11/06.
56. Auerbach BD, Osterweil EK, Bear MF. Mutations causing syndromic autism define an axis of synaptic pathophysiology. Nature. 2011;480(7375):63-8. Epub 2011/11/25.
57. Amir RE, Van den Veyver IB, Wan M, Tran CQ, Francke U, Zoghbi HY. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat Genet. 1999;23(2):185-8. (Pubitemid 29455390)
58. Li E. Chromatin modification and epigenetic reprogramming in mammalian development. Nat Rev Genet. 2002;3(9):662-73. Epub 2002/09/05. (Pubitemid 34984255)
59. Tsankova N, Renthal W, Kumar A, Nestler EJ. Epigenetic regulation in psychiatric disorders. Nat Rev Neurosci. 2007;8(5):355-67. Epub 2007/04/25. (Pubitemid 46652469)
60. Feinberg AP. Epigenetics at the epicenter of modern medicine. JAMA. 2008;299(11):1345-50. Epub 2008/03/20. (Pubitemid 351439080)
61. Berger SL. The complex language of chromatin regulation during transcription. Nature. 2007;447(7143):407-12. Epub 2007/05/25. (Pubitemid 46816746)
62. Wu H, Coskun V, Tao J, Xie W, Ge W, Yoshikawa K, et al. Dnmt3a-dependent nonpromoter DNA methylation facilitates transcription of neurogenic genes. Science. 2010;329 (5990):444-8. Epub 2010/07/24.
63. Holliday R. Epigenetics: a historical overview. Epigenetics: official journal of the DNA Methylation Society. 2006;1(2):76-80. Epub 2007/11/14.
64. Henikoff S, Matzke MA. Exploring and explaining epigenetic effects. Trends in genetics: TIG. 1997;13(8):293-5. Epub 1997/08/01.
65. Elia J, Laracy S, Allen J, Nissley-Tsiopinis J, Borgmann-Winter K. Epigenetics: genetics versus life experiences. Curr Top Behav Neurosci. 2012;9:317-40. Epub 2011/07/06.
66. Archer T, Oscar-Berman M, Blum K. Epigenetics in developmental disorder: ADHD and endophenotypes. Journal of Genetic Syndrome & Gene Therapy. 2011;2(104). Epub 2012/01/09.
67. Vucetic Z, Totoki K, Schoch H, Whitaker KW, Hill-Smith T, Lucki I, et al. Early life protein restriction alters dopamine circuitry. Neuroscience. 2010;168(2):359-70. Epub 2010/04/17.
68. Vucetic Z, Kimmel J, Totoki K, Hollenbeck E, Reyes TM. Maternal high-fat diet alters methylation and gene expression of dopamine and opioid-related genes. Endocrinology. 2010;151 (10):4756-64. Epub 2010/08/06.
69. Andrews SC, Wood MD, Tunster SJ, Barton SC, Surani MA, John RM. Cdkn1c (p57Kip2) is the major regulator of embryonic growth within its imprinted domain on mouse distal chromosome 7. BMC Dev Biol. 2007;7:53. Epub 2007/05/23.
70. Hultman CM, Torrang A, Tuvblad C, Cnattingius S, Larsson JO, Lichtenstein P. Birth weight and attention-deficit/hyperactivity symptoms in childhood and early adolescence: a prospective Swedish twin study. J Am Acad Child Adolesc Psychiatry. 2007;46(3):370-7.
71. Eubig PA, Aguiar A, Schantz SL. Lead and PCBs as risk factors for attention deficit/hyperactivity disorder. Environ Health Perspect. 2010;118(12):1654-67. Epub 2010/09/11.
72. Cho SC, Kim BN, Hong YC, Shin MS, Yoo HJ, Kim JW, et al. Effect of environmental exposure to lead and tobacco smoke on inattentive and hyperactive symptoms and neurocognitive performance in children. J Child Psychol Psychiatry. 2010;51(9):1050-7. Epub 2010/04/22.
73. Kapoor A, Petropoulos S, Matthews SG. Fetal programming of hypothalamic-pituitary-adrenal (HPA) axis function and behavior by synthetic glucocorticoids. Brain Res Rev. 2008;57(2):586-95. Epub 2007/08/25. (Pubitemid 351381772)
74. Linnet KM, Wisborg K, Obel C, Secher NJ, Thomsen PH, Agerbo E, et al. Smoking during pregnancy and the risk for hyperkinetic disorder in offspring. Pediatrics. 2005;116(2):462-7. (Pubitemid 44161475)
75. Thapar A, Fowler T, Rice F, Scourfield J, van den Bree M, Thomas H, et al. Maternal smoking during pregnancy and attention deficit hyperactivity disorder symptoms in offspring. Am J Psychiatry. 2003;160(11):1985-9. Epub 2003/11/05. (Pubitemid 39619635)
76. Kotimaa AJ, Moilanen I, Taanila A, Ebeling H, Smalley SL, McGough JJ, et al. Maternal smoking and hyperactivity in 8-year-old children. J Am Acad Child Adolesc Psychiatry. 2003;42 (7):826-33. (Pubitemid 39571846)
77. Mick E, Biederman J, Faraone SV, Sayer J, Kleinman S. Casecontrol study of attention-deficit hyperactivity disorder and maternal smoking, alcohol use, and drug use during pregnancy. J Am Acad Child Adolesc Psychiatry. 2002;41(4):378-85. Epub 2002/04/05. (Pubitemid 38327913)
78. Milberger S, Biederman J, Faraone SV, Chen L, Jones J. Is maternal smoking during pregnancy a risk factor for attention deficit hyperactivity disorder in children? Am J Psychiatry. 1996;153(9):1138-42. Epub 1996/09/01. (Pubitemid 26299831)
79. Milberger S, Biederman J, Faraone SV, Chen L, Jones J. Further evidence of an association between attention-deficit/hyperactivity disorder and cigarette smoking. Findings from a high-risk sample of siblings. Am J Addict. 1997;6(3):205-17. Epub 1997/07/01. (Pubitemid 27356003)
80. McIntosh DE, Mulkins RS, Dean RS. Utilization of maternal perinatal risk indicators in the differential diagnosis of ADHD and UADD children. Int J Neurosci. 1995;81(1-2):35-46. Epub 1995/03/01.
81. Neuman RJ, Lobos E, Reich W, Henderson CA, Sun LW, Todd RD. Prenatal smoking exposure and dopaminergic genotypes interact to cause a severe ADHD subtype. Biol Psychiatry. 2006.
82. Langley K, Rice F, van den Bree MB, Thapar A. Maternal smoking during pregnancy as an environmental risk factor for attention deficit hyperactivity disorder behaviour. A review. Minerva Pediatr. 2005;57(6):359-71. (Pubitemid 44251940)
83. Braun JM, Kahn RS, Froehlich T, Auinger P, Lanphear BP. Exposures to environmental toxicants and attention deficit hyperactivity disorder in U.S. children. Environ Health Perspect. 2006;114(12):1904-9. Epub 2006/12/23. (Pubitemid 44873693)
84. O'Connor TG, Heron J, Golding J, Beveridge M, Glover V. Maternal antenatal anxiety and children's behavioural/emotional problems at 4 years. Report from the Avon Longitudinal Study of Parents and Children. Br J Psychiatry. 2002;180:502-8. Epub 2002/06/04. (Pubitemid 34596800)
85. Fried PA, Makin JE. Neonatal behavioural correlates of prenatal exposure to marihuana, cigarettes and alcohol in a low risk population. Neurotoxicol Teratol. 1987;9(1):1-7. Epub 1987/01/01. (Pubitemid 18024586)
86. Naeye RL, Peters EC. Mental development of children whose mothers smoked during pregnancy. Obstet Gynecol. 1984;64 (5):601-7. Epub 1984/11/01. (Pubitemid 15205459)
87. O'Callaghan MJ, Williams GM, Andersen MJ, Bor W, Najman JM. Obstetric and perinatal factors as predictors of child behaviour at 5 years. J Paediatr Child Health. 1997;33(6):497-503. Epub 1998/03/04. (Pubitemid 28133729)
88. Huizink AC, Mulder EJ. Maternal smoking, drinking or cannabis use during pregnancy and neurobehavioral and cognitive functioning in human offspring. Neurosci Biobehav Rev. 2006;30 (1):24-41. (Pubitemid 41779405)
89. Knopik VS, Heath AC, Jacob T, Slutske WS, Bucholz KK, Madden PA, et al. Maternal alcohol use disorder and offspring ADHD: disentangling genetic and environmental effects using a children-of-twins design. Psychol Med. 2006;36(10):1461-71. (Pubitemid 44355981)
90. Nigg JT, Breslau N. Prenatal smoking exposure, low birth weight, and disruptive behavior disorders. J Am Acad Child Adolesc Psychiatry. 2007;46(3):362-9.
91. Haavik J, Halmoy A, Hegvik T-A, Johansson S. Maternal genotypes as predictors of offspring mental health: the next frontier of genomic medicine? Futur Neurol. 2011;6:731-43.
92. Wong CC, Caspi A, Williams B, Craig IW, Houts R, Ambler A, et al. A longitudinal study of epigenetic variation in twins. Epigenetics: official journal of the DNA Methylation Society. 2010;5 (6):516-26. Epub 2010/05/28.
93. Shumay E, Fowler JS, Volkow ND. Genomic features of the human dopamine transporter gene and its potential epigenetic States: implications for phenotypic diversity. PLoS One. 2010;5 (6):e11067. Epub 2010/06/16.
94. Choudhry Z, Sengupta SM, Grizenko N, Fortier ME, Thakur GA, Bellingham J, et al. LPHN3 and attention-deficit/hyperactivity disorder: interaction with maternal stress during pregnancy. Journal of child psychology and psychiatry, and allied disciplines. 2012. Epub 2012/04/11.
95. Baird AL, Coogan AN, Siddiqui A, Donev RM, Thome J. Adult attention-deficit hyperactivity disorder is associated with alterations in circadian rhythms at the behavioural, endocrine and molecular levels. Mol Psychiatry. 2011. Epub 2011/11/23.
96. Kraft M, Cirstea IC, Voss AK, Thomas T, Goehring I, Sheikh BN, et al. Disruption of the histone acetyltransferase MYST4 leads to a Noonan syndrome-like phenotype and hyperactivated MAPK signaling in humans and mice. J Clin Invest. 2011;121(9):3479-91. Epub 2011/08/02.
97. Shishkina GT, Kalinina TS, Dygalo NN. Attenuation of alpha2A-adrenergic receptor expression in neonatal rat brain by RNA interference or antisense oligonucleotide reduced anxiety in adulthood. Neuroscience. 2004;129(3):521-8. Epub 2004/11/16. (Pubitemid 39487106)
98. Swanson JM, Volkow ND. Pharmacokinetic and pharmacodynamic properties of stimulants: implications for the design of new treatments for ADHD. Behav Brain Res. 2002;130(1-2):73-8. Epub 2002/02/28. (Pubitemid 34201784)
99. Adriani W, Leo D, Guarino M, Natoli A, Di Consiglio E, De Angelis G, et al. Short-term effects of adolescent methylphenidate exposure on brain striatal gene expression and sexual/endocrine parameters in male rats. Ann N Y Acad Sci. 2006;1074:52-73. Epub 2006/11/16. (Pubitemid 44532810)
100. Yano M, Steiner H. Topography of methylphenidate (ritalin)-induced gene regulation in the striatum: differential effects on cfos, substance P and opioid peptides. Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology. 2005;30(5):901-15. Epub 2005/01/08. (Pubitemid 40570906)
101. Lin JS, Hou Y, Jouvet M. Potential brain neuronal targets for amphetamine-, methylphenidate-, and modafinil-induced wakefulness, evidenced by c-fos immunocytochemistry in the cat. Proc Natl Acad Sci U S A. 1996;93(24):14128-33. Epub 1996/11/26. (Pubitemid 26424257)
102. Kieling C, Genro JP, Hutz MH, Rohde LA. A current update on ADHD pharmacogenomics. Pharmacogenomics. 2010;11 (3):407-19. Epub 2010/03/20.
103. Froehlich T, McGough J, Stein MA. Progress and promise of ADHD pharmacogenetics. CNS Drugs. 2010;24(2):99-117.
104. Polanczyk G, Bigarella MP, Hutz MH, Rohde LA. Pharmacogenetic approach for a better drug treatment in children. Curr Pharm Des. 2010;16(22):2462-73. Epub 2010/06/02.
105. Froehlich TE, Epstein JN, Nick TG, Melguizo Castro MS, Stein MA, Brinkman WB, et al. Pharmacogenetic predictors of methylphenidate dose-response in attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2011;50(11):1129-39. Epub 2011/10/26.
106. Mick E, Neale B, Middleton FA, McGough JJ, Faraone SV. Genome-wide association study of response to methylphenidate in 187 children with attention-deficit/hyperactivity disorder. Am J Med Genet B Neuropsychiatr Genet. 2008;147B(8):1412-8.
107. Mattay VS, Goldberg TE, Fera F, Hariri AR, Tessitore A, Egan MF, et al. Catechol O-methyltransferase val158-met genotype and individual variation in the brain response to amphetamine. Proc Natl Acad Sci U S A. 2003;100(10):6186-91. (Pubitemid 36576952)
108. Hamidovic A, Dlugos A, Palmer AA, de Wit H. Polymorphisms in dopamine transporter (SLC6A3) are associated with stimulant effects of D-amphetamine: an exploratory pharmacogenetic study using healthy volunteers. Behav Genet. 2010;40(2):255-61. Epub 2010/01/22.
109. Gruber R, Joober R, Grizenko N, Leventhal BL, Cook Jr EH, Stein MA. Dopamine transporter genotype and stimulant side effect factors in youth diagnosed with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2009;19 (3):233-9. Epub 2009/06/13.
110. Mick E, McGough JJ, Middleton FA, Neale B, Faraone SV. Genome-wide association study of blood pressure response to methylphenidate treatment of attention-deficit/hyperactivity disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35 (2):466-72. Epub 2010/12/07.
111. Cho SC, Kim BN, Cummins TD, Kim JW, Bellgrove MA. Norepinephrine transporter-3081(A/T) and alpha-2A-adrenergic receptor MspI polymorphisms are associated with cardiovascular side effects of OROS-methylphenidate treatment. J Psychopharmacol. 2012;26(3):380-9. Epub 2011/06/02.
112. Patrick KS, Straughn AB, Minhinnett RR, Yeatts SD, Herrin AE, DeVane CL, et al. Influence of ethanol and gender on methylphenidate pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 2007;81(3):346-53. Epub 2007/03/07. (Pubitemid 46364487)
113. Zhu HJ, Patrick KS, Yuan HJ, Wang JS, Donovan JL, DeVane CL, et al. Two CES1 gene mutations lead to dysfunctional carboxylesterase 1 activity in man: clinical significance and molecular basis. Am J Hum Genet. 2008;82(6):1241-8.
114. Nemoda Z, Angyal N, Tarnok Z, Gadoros J, Sasvari-Szekely M. Carboxylesterase 1 gene polymorphism and methylphenidate response in ADHD. Neuropharmacology. 2009;57(7-8):731-3. Epub 2009/09/08.
115. Michelson D, Read HA, Ruff DD, Witcher J, Zhang S, McCracken J. CYP2D6 and clinical response to atomoxetine in children and adolescents with ADHD. J Am Acad Child Adolesc Psychiatry. 2007;46(2):242-51. Epub 2007/01/24. (Pubitemid 46148423)
116. Trzepacz PT, Williams DW, Feldman PD, Wrishko RE, Witcher JW, Buitelaar JK. CYP2D6 metabolizer status and atomoxetine dosing in children and adolescents with ADHD. Eur Neuropsychopharmacol. 2008;18(2):79-86. Epub 2007/08/19. (Pubitemid 350296843)
117. ter Laak MA, Temmink AH, Koeken A, van 't Veer NE, van Hattum PR, Cobbaert CM. Recognition of impaired atomoxetine metabolism because of low CYP2D6 activity. Pediatr Neurol. 2010;43(3):159-62. Epub 2010/08/10.
118. Scherer D, Hassel D, Bloehs R, Zitron E, von Lowenstern K, Seyler C, et al. Selective noradrenaline reuptake inhibitor atomoxetine directly blocks hERG currents. Br J Pharmacol. 2009;156 (2):226-36. Epub 2009/01/22.
119. Sawant S, Daviss SR. Seizures and prolonged QTc with atomoxetine overdose. Am J Psychiatry. 2004;161(4):757. Epub 2004/04/02. (Pubitemid 38445527)
120. Barker MJ, Benitez JG, Ternullo S, Juhl GA. Acute oxcarbazepine and atomoxetine overdose with quetiapine. Vet Hum Toxicol. 2004;46(3):130-2. Epub 2004/06/03. (Pubitemid 38650083)
121. Kiehn J, Lacerda AE, Brown AM. Pathways of HERG inactivation. Am J Physiol. 1999;277(1 Pt 2):H199-210. Epub 1999/07/17. (Pubitemid 29354694)
122. O'Rourke JA, Scharf JM, Yu D, Pauls DL. The genetics of Tourette syndrome: a review. J Psychosom Res. 2009;67 (6):533-45. Epub 2009/11/17.
123. Mathews CA, Grados MA. Familiality of Tourette syndrome, obsessive-compulsive disorder, and attention-deficit/hyperactivity disorder: heritability analysis in a large sib-pair sample. J Am Acad Child Adolesc Psychiatry. 2011;50(1):46-54. Epub 2010/12/16.
124. Geller D, Petty C, Vivas F, Johnson J, Pauls D, Biederman J. Further evidence for co-segregation between pediatric obsessive compulsive disorder and attention deficit hyperactivity disorder: a familial risk analysis. Biol Psychiatry. 2007;61(12):1388-94. Epub 2007/01/24. (Pubitemid 46855770)
125. DeMille MM, Kidd JR, Ruggeri V, Palmatier MA, Goldman D, Odunsi A, et al. Population variation in linkage disequilibrium across the COMT gene considering promoter region and coding region variation. Hum Genet. 2002;111(6):521-37. (Pubitemid 36075084)
126. Mrazek DA. Current applications of clinical genetic testing for psychiatric practice. Minn Med. 2007;90(1):42-43
127. Lyon GJ, Jiang T, VanWijk R, Wang W, Bodily PM, Xing J, et al. Exome sequencing and unrelated findings in the context of complex disease research: ethical and clinical implications. Discov Med. 2011;12(62):41-55. Epub 2011/07/29.
128. Homer N, Szelinger S, Redman M, Duggan D, Tembe W, Muehling J, et al. Resolving individuals contributing trace amounts of DNA to highly complex mixtures using highdensity SNP genotyping microarrays. PLoS Genet. 2008;4(8): e1000167. Epub 2008/09/05.
129. Braun R, Rowe W, Schaefer C, Zhang J, Buetow K. Needles in the haystack: identifying individuals present in pooled genomic data. PLoS Genet. 2009;5(10):e1000668. Epub 2009/10/03.
130. Clifton JM, VanBeuge SS, Mladenka C, Wosnik KK. The genetic information nondiscrimination act 2008: what clinicians should understand. J Am Acad Nurse Pract. 2010;22(5):246-9. Epub 2010/05/27.
131. Vaccarino FM, Urban AE, Stevens HE, Szekely A, Abyzov A, Grigorenko EL, et al. Annual research review: the promise of stem cell research for neuropsychiatric disorders. J Child Psychol Psychiatry. 2011;52(4):504-16. Epub 2011/01/06.
132. Hess EJ, Collins KA, Wilson MC. Mouse model of hyperkinesis implicates SNAP-25 in behavioral regulation. The Journal of neuroscience: the official journal of the Society for Neuroscience. 1996;16(9):3104-11. Epub 1996/05/01. (Pubitemid 26121853)